BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $068270.KS readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07093476-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Metformin readout (P3) · Celltrion $068270.KS
DESCRIPTION:Efficacy and Safety of Add-On Therapy With Empagliflozin in Pat
 ients With Type 2 Diabetes on a Background of Alogliptin and Metformin\n\n
 Primary completion date: 2026-12 (estimated) — month only\, shown on the
  1st\nPhase 3 · Cardio-Met · T2DM\, Diabete Type 2\, DM\nEnrollment: 171
  · Sites: 1\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT07093476\nhttps://clinicaltrials.gov/study/NCT0
 7093476
URL:https://datacutoff.com/radar.html?nct=NCT07093476
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939595-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~CT-P51 readout (P3) · Celltrion $068270.KS
DESCRIPTION:A Study to Compare Effects and Safety of CT-P51 and Keytruda in
  Patients With Previously Untreated Metastatic Lung Cancer\n\nPrimary comp
 letion date: 2027-02 (estimated) — month only\, shown on the 1st\nPhase 
 3 · Oncology · Non Squamous Non Small Cell Lung Cancer\nEnrollment: 225 
 · Sites: 1\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://datacut
 off.com/radar.html?nct=NCT06939595\nhttps://clinicaltrials.gov/study/NCT06
 939595
URL:https://datacutoff.com/radar.html?nct=NCT06939595
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:CT-P44(Daratumumab) readout (P3) · Celltrion $068270.KS
DESCRIPTION:A Study to Compare Pharmacokinetics\, Efficacy and Safety of Su
 bcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and
  Dexamethasone in Patients With Refractory …\n\nPrimary completion date:
  2027-03-08 (estimated)\nOriginally planned: 2027-11-15 (-8.3 months)\nPha
 se 3 · Oncology · Refractory or Relapsed Multiple Myeloma\nEnrollment: 4
 73 · Sites: 1\n\nPrimary completion = last participant's primary-endpoint
  data collected\; topline results usually follow weeks to months later. Sp
 onsor-reported\, often an estimate. Not investment advice.\n\nhttps://data
 cutoff.com/radar.html?nct=NCT06952478\nhttps://clinicaltrials.gov/study/NC
 T06952478
URL:https://datacutoff.com/radar.html?nct=NCT06952478
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
